← Leaderboards
Todd D Giorgio
Vanderbilt University
$1,175,390
Attributed
$2,451,541
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $475.3K · FY2017–23$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,451,541 · 4
By mechanism
R01$1,914,227 · 1
R21$334,694 · 1
U54$202,620 · 2
Top collaborators
- Dineo Khabele6 shared
- Fiona E Yull6 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Lynn M Matrisian$19,522,211
- Jennifer A Pietenpol$43,416,854
- Yu Shyr$30,935,638
- Harold L Moses$33,288,478
- Ann Richmond$15,857,391
Others in their field
Top investigators on “Cancer Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,605,292
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- Leonard Freedman · Leidos Biomedical Research, Inc.$66,901,020
- Charles A Coltman · Southwest Oncology Group$64,795,252
- Norman Wolmark · Nsabp Foundation, Inc.$63,442,676
Research focus
Cancer ImmunotherapyImmunotherapyTumor BurdenTumorMouse ModelMalignant Female Reproductive System NeoplasmImmuneInnovationMalignant Neoplasm Of OvaryPeritonealTumor ProgressionDesignGynecologic OncologyHuman DiseaseCellsCancer TherapyImmune ResponseBaseLeadAscitesAntitumor EffectExhibitsFlow CytometryI Kappa B-Alpha
Grant awards (11)
Project 1: Developing immune checkpoint controlled-release biomaterials for cancer immunotherapy$50,237
U54 · FY2023 · CA · contact PI
Project 1: Developing immune checkpoint controlled-release biomaterials for cancer immunotherapy$101,121
U54 · FY2022 · CA · contact PI
Macrophage-based ovarian cancer immunotherapy$424,055
R01 · FY2021 · CA
Project 1: Developing immune checkpoint controlled-release biomaterials for cancer immunotherapy$51,262
U54 · FY2021 · CA · contact PI
Macrophage-based ovarian cancer immunotherapy$358,694
R01 · FY2020 · CA
Macrophage-based ovarian cancer immunotherapy$53,152
R01 · FY2020 · CA
Macrophage-based ovarian cancer immunotherapy$347,926
R01 · FY2019 · CA
Macrophage-based ovarian cancer immunotherapy$358,683
R01 · FY2018 · CA
Macrophage-based ovarian cancer immunotherapy$371,717
R01 · FY2017 · CA
Combinatorial Peptidomimetics as Antineoplastics$167,330
R21 · FY2003 · CA
Combinatorial Peptidomimetics as Antineoplastics$167,364
R21 · FY2002 · CA